Drugs / SEMZUVOLIMAB
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04620291 | Dec 2023 → Dec 2025 | HIV infectious disease | United BioPharma | Unknown | No outcome recorded |
| Phase 1 | NCT04620304 | Jan 2021 → May 2022 | HIV infectious disease | United BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT01140126 | May 2010 → Jul 2011 | — | United Biomedical | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05582694 | Jul 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04985890 | Mar 2024 → Dec 2026 expected | HIV infectious disease | UBP Greater China (Shanghai) Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04404049 | Dec 2023 → Jun 2024 | HIV infectious disease | UBP Greater China (Shanghai) Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03164447 | Dec 2023 → Mar 2024 | HIV infectious disease | United BioPharma | Unknown | No outcome recorded |
| Phase 2 | NCT05056974 | Dec 2021 → Feb 2023 | HIV infectious disease | United BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT04041362 | Apr → Dec 2020 | HIV infectious disease | United BioPharma | Withdrawn | No outcome recorded |
| Phase 2 | NCT03743376 | Dec 2018 → Oct 2020 | HIV infectious disease | United BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT02369146 | Jun 2015 → Jul 2016 | HIV infectious disease | United BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT01668043 | Sep 2012 → Mar 2014 | — | United Biomedical | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03149211 | Apr → Dec 2025 | HIV infectious disease | United BioPharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT04406727 | Dec 2023 → Jun 2026 | HIV infectious disease | United BioPharma | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEMZUVOLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297846 ↗ |
| Known as | Db4c7 mab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297846 ↗ |
| Known as | dB4C7C22-6 | “The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution.” NCT04620304 ↗1“The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution.” NCT04620291 ↗ |
| Known as | Mab db4c7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297846 ↗ |
| Known as | UB-421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05056974 ↗ |
| Known as | UB-421 (DB4C7 MAB) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297846 ↗ |
| Action | Inhibit | “The neutralizing activity of UB-421 blocks HIV-1 from binding to its receptor on CD4-positive cells” NCT01140126 ↗ |
| Modality | Protein / enzyme biologic | “the antibody (UB-421)” NCT01668043 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT01140126 ↗ |
| Target | CD4 | “targeting the HIV-1 receptor on the CD4 molecule (domain 1)” NCT01140126 ↗ |